Thanks. I do understand that there would almost definately be greater interest from investors on that side, and opportunities to possibly fund drugs further down the path, but surely in the end it still amounts to dilution and i would think if it listed they would go big. Existing holders would likely end up with less than 50% of final outcome. Unless mr Trbe plans to buy large on nasdaq surely it wouldnt be in his interest. i guess the only theory is part of a big co.pany with commercial drugs and funding is better than all of a research vehicle. That being said until we can demonstrate efficacy on some major disease target outside this very specific eye condition one would think they will stay as they are for now.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)